Paul Cannell

2.2k total citations
55 papers, 1.1k citations indexed

About

Paul Cannell is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Paul Cannell has authored 55 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Hematology, 19 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in Paul Cannell's work include Multiple Myeloma Research and Treatments (11 papers), Acute Myeloid Leukemia Research (10 papers) and Acute Lymphoblastic Leukemia research (10 papers). Paul Cannell is often cited by papers focused on Multiple Myeloma Research and Treatments (11 papers), Acute Myeloid Leukemia Research (10 papers) and Acute Lymphoblastic Leukemia research (10 papers). Paul Cannell collaborates with scholars based in Australia, United States and United Kingdom. Paul Cannell's co-authors include Gavin Cull, Richard Herrmann, Duncan Purtill, Julian Cooney, John J. Moore, M. Händel, R. Will, Dávid Ma, Elizabeth Lobb and Letizia Foroni and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Paul Cannell

50 papers receiving 1.1k citations

Peers

Paul Cannell
Andrew R. Rezvani United States
Oumédaly Reman France
Esteban Abella United States
Silvia Park South Korea
Emma Das‐Gupta United Kingdom
Peter Duggan Canada
Francesco Nobile Italy
Philippe Mineur Belgium
Masahito Tsurusawa Japan
Felix Keil Austria
Andrew R. Rezvani United States
Paul Cannell
Citations per year, relative to Paul Cannell Paul Cannell (= 1×) peers Andrew R. Rezvani

Countries citing papers authored by Paul Cannell

Since Specialization
Citations

This map shows the geographic impact of Paul Cannell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Cannell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Cannell more than expected).

Fields of papers citing papers by Paul Cannell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Cannell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Cannell. The network helps show where Paul Cannell may publish in the future.

Co-authorship network of co-authors of Paul Cannell

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Cannell. A scholar is included among the top collaborators of Paul Cannell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Cannell. Paul Cannell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Purtill, Duncan, et al.. (2023). Letermovir for pre‐emptive cytomegalovirus therapy after allogeneic hematopoietic cell transplantation. Transplant Infectious Disease. 25(S1). e14147–e14147. 4 indexed citations
3.
Popat, Rakesh, Bradley Augustson, Mercedes Gironella, et al.. (2023). Belantamab Mafodotin in Combination with Lenalidomide Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Analysis of DREAMM-6 Trial Arm-a. Blood. 142(Supplement 1). 2010–2010. 2 indexed citations
4.
5.
Lam, Wei‐Sen, et al.. (2022). Specialist pharmacist consultations with cancer patients in a pharmacist‐led anticancer clinic. Asia-Pacific Journal of Clinical Oncology. 19(4). 507–516. 2 indexed citations
6.
7.
Boan, Peter, et al.. (2021). High dose valaciclovir to prevent cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients. Transplant Infectious Disease. 23(4). e13633–e13633. 2 indexed citations
8.
Hiddemann, Wolfgang, Anna Maria Barbui, Miguel Canales, et al.. (2018). Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. Journal of Clinical Oncology. 36(23). 2395–2404. 144 indexed citations
9.
Hiddemann, Wolfgang, Anna Maria Barbui, Miguel Canales, et al.. (2017). Immunochemotherapy With Obinutuzumab Or Rituximab In Previously Untreated Follicular Lymphoma In The Randomized Phase III Gallium Study: Analysis By Chemotherapy Regimen. Haematologica. 1 indexed citations
10.
11.
Herrmann, Richard, Marian Sturm, Kathryn Shaw, et al.. (2011). Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study. International Journal of Hematology. 95(2). 182–188. 71 indexed citations
12.
Thin, Lena, Gerry MacQuillan, Leon A. Adams, et al.. (2009). Acute graft-versus-host disease after liver transplant: Novel use of etanercept and the role of tumor necrosis factor α inhibitors. Liver Transplantation. 15(4). 421–426. 25 indexed citations
13.
Moore, John J., Dávid Ma, R. Will, et al.. (2004). A phase II study of Rituximab in rheumatoid arthritis patients with recurrent disease following haematopoietic stem cell transplantation. Bone Marrow Transplantation. 34(3). 241–247. 29 indexed citations
14.
Moore, John J., Peter Brooks, Sam Milliken, et al.. (2002). A pilot randomized trial comparing CD34‐selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis. Arthritis & Rheumatism. 46(9). 2301–2309. 125 indexed citations
15.
Snowden, John A., John J. Moore, Paul Cannell, et al.. (2001). Autologous stem cell transplantation in rheumatoid arthritis. eCite Digital Repository (University of Tasmania). 3 indexed citations
16.
Witt, Campbell S., et al.. (2000). Unrelated donors selected prospectively by block-matching have superior bone marrow transplant outcome. Human Immunology. 61(2). 85–91. 15 indexed citations
17.
Cull, Gavin, et al.. (1997). Collection and Recruitment of CD34+ Cells During Large-Volume Leukapheresis. Journal of Hematotherapy. 6(4). 309–314. 35 indexed citations
18.
Cull, Gavin, John W. Eikelboom, & Paul Cannell. (1997). Exacerbation of coagulopathy with concurrent bone marrow necrosis, hepatic and renal dysfunction secondary to all-trans retinoic acid therapy for acute promyelocytic leukemia. Hematological Oncology. 15(1). 13–17. 1 indexed citations
19.
Foroni, Letizia, Mary Papaioannou, Paul Cannell, et al.. (1997). Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukaemia reveals differences in treatment response. Leukemia. 11(10). 1732–1741. 60 indexed citations
20.
Chim, Chor Sang, Luke Coyle, John C. Yaxley, et al.. (1996). The use of IgH fingerprinting and ASO‐dependent PCR for the investigation of residual disease (MRD) in ALL. British Journal of Haematology. 92(1). 104–115. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andrew R. Rezvani Breakdown of academic impact, for papers by Oumédaly Reman Breakdown of academic impact, for papers by Esteban Abella Breakdown of academic impact, for papers by Silvia Park Breakdown of academic impact, for papers by Emma Das‐Gupta Breakdown of academic impact, for papers by Peter Duggan Breakdown of academic impact, for papers by Francesco Nobile Breakdown of academic impact, for papers by Philippe Mineur Breakdown of academic impact, for papers by Masahito Tsurusawa Breakdown of academic impact, for papers by Felix Keil
Rankless by CCL
2026